Compare GSK plc (GSK) vs Invesco Preferred ETF (PGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs Invesco Preferred ETF — how do they compare? GSK plc trades at $46.32 (market cap $91.88B), while Invesco Preferred ETF trades at $9.99 (market cap $3.60B). The key difference: GSK plc is far larger — about 25.5× Invesco Preferred ETF's market cap, and GSK plc pays a 3.9% dividend while Invesco Preferred ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold GSK plc for 93 Days and Invesco Preferred ETF for 94 Days on average.
| GSK | PGX | |
|---|---|---|
Market Cap | $91.88B | $3.60B |
Volume | 7,730,529 | 5,986,026 |
Sector | Health | — |
52-Week High | $61.18 | $11.61 |
52-Week Low | $43.24 | $9.97 |
Typical Hold Time | 93 Days | 94 Days |
Enterprise Value | $111.88B | — |
Dividend Yield | 3.9% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK trades at $47.02, up 0.9% with a P/E of 14.89, trading below industry averages. The stock shows strong profitability with 72.73% gross margins and 29.73% ROE, though technical indicators signal bearish momentum. Recent earnings beats and strategic oncology investments highlight growth potential amid patent cliff concerns.
GSK's valuation appears attractive with earnings momentum, but faces headwinds from technical weakness and HIV patent expirations. The bullish analyst sentiment (31% buy ratings) and pipeline innovation provide upside, while cost-saving initiatives and dividend yield offer stability. Key risks include competitive pressures and execution on £40B sales targets.
PGX trades at $10.005, up 0.35% today, but technical indicators signal a bearish trend with moving averages and ADX pointing lower. The stock lacks disclosed financial ratios such as P/E and P/S, and no recent income statement or cash flow data is available. Recent corporate actions include dividend payments scheduled for 2026, but current fundamental metrics are not provided.
The outlook for PGX is cautious due to the absence of current financial data and bearish technical signals. Investment opportunities hinge on future earnings visibility and valuation clarity, while risks include potential earnings volatility and market sentiment shifts. Investors should await updated financial disclosures for a clearer assessment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About Invesco Preferred ETF
The fund generally will invest at least 80% of its total assets in the components of the index. Strictly in accordance with its guidelines and mandated procedures, ICE Data Indices, LLC selects securities for the index, which is a market capitalization-weighted index designed to measure the performance of the fixed rate US dollar-denominated preferred securities market.
Read more on PGX →
